Comparison of the effect of intravitreal injection of conbercept with different doses in the treatment of retinopathy of prematurity / 中华眼底病杂志

ABSTRACT

Objective:To observe the effect of intravitreal injection of Conbercept with two different doses in the treatment of retinopathy of prematurity (ROP) and explore the clinical feasibility of ROP treatment by lower dose conbercept.Methods:This was a prospective study. The premature infants were enrolled with pre-threshold type 1, threshold and acute aggressive posterior retinopathy of prematurity (AP-ROP) from March 2018 to June 2019, who received fundus screening in neonatal intensive care unit (NICU) of Henan Provincial People's Hospital, Henan Eye Hospital. They were randomly divided into two groups. The group A (lower dose group) were received intravitreal injection of conbercept with 0.15 mg/0.015 ml, and those in group B (control group) were received intravitreal injection of conbercept with 0.25 mg/0.025 ml. We checked and recorded the lesion area, stage, scope (according to the clock range), additional lesion (plus), etc. Fundus examination should be performed with the pediatric wide-field fundus imaging system within 7 days after treatment. It was used to observe the plus disese, ridge, regression of neovascularization on ridge, and development of retinal vessels to serrated edge or scarring. The follow-up period was at least 24 weeks. The effect evaluation was divided into recovery, improvement, recurrence and aggravation.Results:The 43 ROP subjects (84 eyes) were enrolled including 21 cases (40 eyes) in group A and 22 (44 eyes) in group B. There was no significant difference between the two groups in gender ( χ2=1.169), birth age ( t=0.283), birth weight ( t=0.547), hospitalization days in NICU ( t=1.187), first examination time ( t=1.811), first injection time ( t=0.492), follow-up time ( t=0.899) and ROP condition ( χ2=0.854) ( P>0.05). In group A, 21 eyes (52.5%) were cured, 17 eyes (42.5%) were improved, 2 eyes (5.0%) were recurred, and no aggravating cases were found. In group B, 24 eyes (54.5%) were cured, 14 eyes (31.8%) were improved, 6 eyes (13.6%) were recurred, and no aggravating cases were found. There was no significant difference of the cure rate ( χ2=2.210, P>0.05) and effective (recovery and improvement) rate ( χ2=1.814, P=0.269) between two groups after the first injection. Conclusion:Intravitreal injection of conbercept with the two doses should be effective in the treatment of ROP.